-
Income Statement
-
Balance Sheet
-
Cashflow Statement
-
Profitability
-
Ratios
Boston Scientific Corporation Income Statement
| Chart | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Revenue |
|
$9.91B | $11.89B | $12.68B | $14.24B |
| Cost of Revenue |
|
$3.51B | $3.76B | $4.00B | $4.35B |
| Gross Profit |
|
$6.40B | $8.13B | $8.68B | $9.90B |
| Research & Development |
|
$1.14B | $1.20B | $1.32B | $1.41B |
| Selling,General & Administrative |
|
$3.79B | $4.36B | $4.52B | $5.19B |
| Operating Expense |
|
$5.72B | $6.30B | $6.65B | $7.55B |
| Operating Income |
|
$1.04B | $2.04B | $1.65B | $2.34B |
| Net Income |
|
-$140.00M | $1.04B | $698.00M | $1.59B |
Boston Scientific Corporation Balance Sheet
| Chart | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Cash and Cash Equivalents |
|
$1.73B | $1.93B | $928.00M | $865.00M |
| Inventories |
|
$1.35B | $1.61B | $1.87B | $2.48B |
| Total Current Assets |
|
$6.69B | $6.32B | $5.76B | $6.51B |
| Property,Plant and Equipment |
|
$2.54B | $2.69B | $2.83B | $3.30B |
| Goodwill |
|
$9.95B | $11.99B | $12.92B | $14.39B |
| Total Assets |
|
$30.78B | $32.23B | $32.47B | $35.14B |
| Total Liabilities |
|
$15.45B | $15.61B | $14.90B | $15.61B |
| Retained Earnings |
|
-$2.38B | -$1.39B | -$750.00M | $819.00M |
| Total Shareholder Equity |
|
$15.33B | $16.62B | $17.57B | $19.28B |
| Common Stock |
|
$17.00M | $17.00M | $17.00M | $17.00M |
Boston Scientific Corporation Cash flow
| Chart | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Depreciation & Amortization |
|
$1.12B | $1.09B | $1.14B | $1.20B |
| Dividends Payout |
|
-$28.00M | -$55.00M | -$55.00M | -$28.00M |
| Capital Expenditures (Capex) |
|
-$376.00M | -$554.00M | -$612.00M | -$800.00M |
| Free Cash Flow (FCF) |
|
$1.13B | $1.32B | $914.00M | $1.70B |
Boston Scientific Corporation Profitability
| Chart | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Gross Profit |
|
$6.40B | $8.13B | $8.68B | $9.90B |
| Gross Profit Margin (%) |
|
64.59% | 68.37% | 68.44% | 69.49% |
| Operating Income |
|
$1.04B | $2.04B | $1.65B | $2.34B |
| Operating Income Margin (%) |
|
10.53% | 17.19% | 13.00% | 16.45% |
| Net Income |
|
-$140.00M | $1.04B | $698.00M | $1.59B |
| Net Income Margin (%) |
|
-1.41% | 8.76% | 5.50% | 11.19% |
| EBITDA |
|
$1.51B | $2.52B | $2.74B | $3.45B |
| EBITDA Margin (%) |
|
18.49% | 23.42% | 22.08% | 24.25% |
Boston Scientific Corporation Ratios
| Chart | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Return on Equity (ROE) |
|
-0.91% | 6.26% | 3.97% | 8.26% |
| Return on Assets (ROA) |
|
-0.45% | 3.23% | 2.15% | 4.53% |
| Debt to Equity |
|
59.57% | 54.50% | 50.81% | 47.18% |
| Debt to total asset |
|
29.67% | 28.11% | 27.50% | 25.89% |
| Enterprise value to revenue |
|
5.93 | 5.72 | 5.88 | 6.50 |
| Enterprise value to EBITDA |
|
38.87 | 26.98 | 27.20 | 26.82 |
| Enterprise value |
|
$58.74B | $67.95B | $74.54B | $92.62B |
| Cash to Debt |
|
16.52% | 20.64% | 17.09% | 27.51% |
| Tax Rate (%) |
|
-1.45% | 3.35% | 38.83% | 19.80% |
| Payout Ratio |
|
-20.00% | 5.28% | 7.88% | 1.76% |
